ClinicalTrials.gg
CompletedNCT03194893Updated Oct 9, 2026Results posted

A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

A Phase 3 interventional study of Alectinib and Crizotinib in Neoplasms, sponsored by Hoffmann-La Roche. Completed at 29 sites in 9 countries. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Updated Oct 9, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Sex
All
01

Study summary

The purpose of this study is to provide continued treatment with alectinib or crizotinib as applicable to participants with ALK- or RET positive cancer who were previously enrolled in any Roche-sponsored alectinib study and who are deriving continued clinical benefit from alectinib or crizotinib in the parent trial at the time of parent trial closure.

02

Conditions studied

  • Neoplasms

Keywords

  • Non-small cell lung cancer (NSCLC)
  • Anaplastic lymphoma kinase (ALK)
  • Rearranged during transfection (RET)
  • Alectinib
  • Crizotinib
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.

This study's enrollment of 50 is below the median of 60 across 7,706 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants enrolled in a Roche-sponsored alectinib trial who are experiencing a clinical benefit from alectinib or crizotinib treatment at the time of discontinuation from the parent trial and for whom a switch to commercial supply is not feasible
  • Collected study termination data, including efficacy and safety data, as required by the parent study on the electronic Case Report Form (eCRF)
  • For women who are not (≥ 12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to remain abstinent or use single or combined methods that result in a failure rate of \< 1% per year during the treatment period and for at least 3 months after the last dose of study drug
  • For men: agreement to remain abstinent or use a contraceptive method that results in a failure rate of \< 1% per year during the treatment period and for at least 3 months after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • Evidence of lack of clinical benefit in parent trial during the screening phase of this rollover study
  • Permanent discontinuation of alectinib or crizotinib for any reason during the parent study or before first dose of study drug in the rollover study
  • Evidence of an adverse event for which the parent protocol stipulates permanent discontinuation
  • Pregnant or breastfeeding women
  • Ongoing serious adverse event that has not resolved to baseline level or Grade ≤1 prior to first dose of study treatment in the rollover study
  • Treatment interruption for more than 21 days due to an adverse event since the last administration of alectinib or crizotinib in the parent trial. Any ongoing adverse events that require temporary treatment interruption must be resolved to baseline grade or assessed as stable and not requiring further treatment interruption by the investigator
  • Administration of strong/potent cytochrome P450 (CYP) 3A inhibitors or inducers within 14 days prior to the first dose of treatment on this study and while on treatment with crizotinib
  • Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol requirements and/or follow-up procedures; these conditions should be discussed with the participant before trial entry
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Alectinib

    Participants will receive alectinib at the same dose and schedule and according to the same administration guidelines as they received at the time of discontinuation from the parent trial.

    Drug: Alectinib

  • Experimental
    Crizotinib

    Participants will receive crizotinib at the same dose and schedule and according to the same administration guidelines as they received at the time of discontinuation from the parent trial.

    Drug: Crizotinib

Interventions

  • Alectinib capsules 600 mg twice a day (BID) orally until no further clinical benefit is to be expected, unacceptable toxicity, availability of commercial supply, withdrawal of consent, or death, whichever occurs first.

  • Crizotinib capsules 250 mg BID orally until no further clinical benefit is to be expected, unacceptable toxicity, availability of commercial supply, withdrawal of consent, or death, whichever occurs first.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI)

    An AE is any untoward medical occurrence in a participant administered a study drug, regardless of causal relationship. A SAE is any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is a medically important event. AESI included drug induced liver injury that include an elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) in combination with either an elevated bilirubin or clinical jaundice and suspected transmission of infectious agent via study drug.

    Time frame: From study initiation until 4 weeks after the last dose (up to approximately 8.19 years)

Secondary outcomes

  1. Number and Causes of Death on Study

    Time frame: Up to approximately 8.19 years

07

Results

Posted Oct 9, 2026

Participant flow

A total of 50 participants with anaplastic lymphoma kinase (ALK)-positive or rearranged during transfection (RET)-positive cancer took part in the rollover study at 30 investigative sites across 9 countries from 5 July 2017 to 18 September 2025.

Participant flow — Overall Study
MilestoneAlectinib
Started50
Completed35
Not completed15
Withdrew: Death1
Withdrew: Progressive disease1
Withdrew: Withdrawal by subject1
Withdrew: Reason not specified12

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI)

An AE is any untoward medical occurrence in a participant administered a study drug, regardless of causal relationship. A SAE is any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is a medically important event. AESI included drug induced liver injury that include an elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) in combination with either an elevated bilirubin or clinical jaundice and suspected transmission of infectious agent via study drug.

Time frame:
From study initiation until 4 weeks after the last dose (up to approximately 8.19 years)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI)
ParticipantsAlectinib
AEs36
SAEs6
AESI0
SecondaryNumber and Causes of Death on Study
Time frame:
Up to approximately 8.19 years
Reported as:
Count of participants · Participants
Number and Causes of Death on Study
ParticipantsAlectinib
Number and Causes of Death on Study1

Adverse events

Collected over From study initiation until 4 weeks after the last dose (up to approximately 8.19 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Alectinib1/50 (2%)6/50 (12%)23/50 (46%)
Most frequent serious events
Most frequent serious events
EventAlectinib
PainGeneral disorders1/50
PneumoniaInfections and infestations1/50
Respiratory tract infectionInfections and infestations1/50
SalmonellosisInfections and infestations1/50
Cerebrovascular accidentNervous system disorders1/50
SeizureNervous system disorders1/50
HaemoptysisRespiratory, thoracic and mediastinal disorders1/50
Most frequent other events
Most frequent other events
EventAlectinib
HeadacheNervous system disorders6/50
AstheniaGeneral disorders5/50
DyspnoeaRespiratory, thoracic and mediastinal disorders5/50
Blood creatine phosphokinase increasedInvestigations4/50
DysphagiaGastrointestinal disorders3/50
NauseaGastrointestinal disorders3/50
VomitingGastrointestinal disorders3/50
Oedema peripheralGeneral disorders3/50
Muscle spasmsMusculoskeletal and connective tissue disorders3/50
Productive coughRespiratory, thoracic and mediastinal disorders3/50

Baseline characteristics

Safety Population included all enrolled participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(Years)Alectinib
Mean56.6 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)Alectinib
Female30
Male20
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Alectinib
Hispanic or Latino1
Not Hispanic or Latino44
Unknown or Not Reported5
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Alectinib
American Indian or Alaska Native0
Asian6
Native Hawaiian or Other Pacific Islander0
Black or African American1
White37
More than one race0
Unknown or Not Reported6
08

Study locations

29 sites
  • Chao Family Comprehensive Cancer Center
    Orange, California 92868, United States
  • Massachusetts General Hospital Cancer Center
    Boston, Massachusetts 02114, United States
  • Centre Francois Baclesse
    Caen, 14076, France
  • Centre Georges François Leclerc
    Dijon, 21000, France
  • Centre Oscar Lambret
    Lille, 59020, France
  • Centre Leon Berard
    Lyon, 69008, France
  • Groupe Hospitalier Sud - Hôpital Haut Lévêque
    Pessac, 33600, France
  • Hopital Pontchaillou - CHU de Rennes
    Rennes, 35033, France
  • CHU de Toulouse - Hôpital Larrey
    Toulouse, 31059, France
  • Hopital Robert Schuman
    Vantoux, 57070, France
  • Queen Mary Hospital
    Hong Kong, Hong Kong
  • Queen Elizabeth Hospital Department of Clinical Oncology
    Kowloon, Hong Kong
  • Irccs Centro Di Riferimento Oncologico (CRO)
    Aviano, Friuli Venezia Giulia 33081, Italy
  • Azienda Ospedaliera San Camillo Forlanini - Unità Operativa Complessa di Pneumologia Oncologica 1
    Rome, Lazio 00151, Italy
  • Azienda Ospedaliero-Universitaria Careggi
    Florence, Tuscany 50139, Italy
  • Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia
    Perugia, Umbria 06132, Italy
  • Uniwersyteckie Centrum Kliniczne
    Gda?sk, 80-214, Poland
  • FSBSI "Russian Oncological Scientific Center n.a. N.N. Blokhin"
    Moscow, Moscow Oblast 115478, Russia
  • University ?linic of headaches
    Moscow, Moscow Oblast 121467, Russia
  • City Clinical Oncology Hospital
    Moscow, Moscow Oblast 143423, Russia
  • Seoul National University Hospital
    Seoul, 03080, South Korea
  • Samsung Medical Center
    Seoul, 06351, South Korea
  • Hospital del Mar
    Barcelona, 08003, Spain
  • Hospital Universitari Dexeus - Grupo Quironsalud
    Barcelona, 08028, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Adana Ac?badem Hospital Oncology Department
    Adana, 01130, Turkey (Türkiye)
  • Istanbul Uni Capa Medical Faculty
    Istanbul, 34093, Turkey (Türkiye)
  • Ege University Medical Faculty
    Izmir, 35040, Turkey (Türkiye)
  • Hacettepe Uni Medical Faculty Hospital
    S?hhiye, Ankara, 06100, Turkey (Türkiye)
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2017 to primary completion in Sep 2025, 98 months.

Results were first posted in Oct 2026, 1 year after primary completion.

Of 119 industry-sponsored phase 3 interventional studies under Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 72. This study's 98 months is above that.

Counting every sponsor, half of 202 studies reached it within 50 months; a quarter within 33 and three quarters within 84.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2017
First posted
Jun 21, 2017
StartActual
Jul 5, 2017
Primary completionActual
Sep 18, 2025
CompletionActual
Sep 18, 2025
Results first posted
Oct 9, 2026
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 9, 2026
Primary outcomes
1 edited, 1 removed
What changed in the outcomes
  • EditedNumber of Patients withParticipants With Adverse Events (AEs), Serious Adverse Events (SAEs), Non-serious Adverse Events (non-SAEs) and Adverse Events of Special Interest (AESI)Time frame: From first dose of study treatment and until the safety follow-up visit (4 weeks after the last dose of study treatment) → From study initiation until 4 weeks after the last dose (up to approximately 8.19 years)
  • RemovedNumber of Patients With Clinically Significant Laboratory Values as per Protocol for Selected Safety Laboratory ParametersTime frame: From first dose of study treatment and until the safety follow-up visit (4 weeks after the last dose of study treatment)
Oct 9, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedNumber and Causes of Death Occurring on StudyTime frame: From first dose of study treatment and until the safety follow-up visit (4 weeks after the last dose of study treatment) → Up to approximately 8.19 years
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Results posted
    Primary outcomes 1 edited, 1 removed
    What changed in the outcomes
    • EditedNumber of Patients withParticipants With Adverse Events (AEs), Serious Adverse Events (SAEs), Non-serious Adverse Events (non-SAEs) and Adverse Events of Special Interest (AESI)Time frame: From first dose of study treatment and until the safety follow-up visit (4 weeks after the last dose of study treatment) → From study initiation until 4 weeks after the last dose (up to approximately 8.19 years)
    • RemovedNumber of Patients With Clinically Significant Laboratory Values as per Protocol for Selected Safety Laboratory ParametersTime frame: From first dose of study treatment and until the safety follow-up visit (4 weeks after the last dose of study treatment)
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedNumber and Causes of Death Occurring on StudyTime frame: From first dose of study treatment and until the safety follow-up visit (4 weeks after the last dose of study treatment) → Up to approximately 8.19 years
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03194893
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 21, 2017
Start date
Jul 5, 2017
Primary completion
Sep 18, 2025
Completion
Sep 18, 2025
Results posted
Oct 9, 2026
Last update
Oct 9, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Alectinib · Crizotinib

Start the discussion